Table 3. ORR Subgroup Analysis in the Efficacy-Evaluable Population.
Patient Subgroup | No./Total No. of Patients | ORR, % (90% CI)a |
---|---|---|
All | 11/60 | 18 (11-29) |
Platinum status | ||
Resistant | 6/29 | 21 (9-37) |
Refractory | 2/16 | 13 (2-34) |
Not applicableb | 3/15 | 20 (6-44) |
Prior lines of therapyc | ||
1-2 | 7/25 | 28 (14-46) |
≥3 | 4/35 | 11 (4-24) |
Prior bevacizumab use | ||
Yes | 7/37 | 19 (9-33) |
No | 4/23 | 17 (6-36) |
tBRCA statusd | ||
tBRCAmut | 2/11 | 18 (3-47) |
tBRCAwt | 9/47 | 19 (10-31) |
PD-L1 statusd | ||
Positive | 7/33 | 21 (10-36) |
Negative | 2/21 | 10 (2-27) |
HRD statusd | ||
HRD positive | 3/21 | 14 (4-33) |
HRD negative | 6/32 | 19 (9-34) |
Abbreviations: HRD, homologous recombination deficiency; ORR, objective response rate; PD-L1, programmed death-ligand 1; tBRCA, tumor BRCA; tBRCAmut, tumor BRCA mutation; tBRCAwt, tumor BRCA wild type.
Includes only confirmed responses using Response Evaluation Criteria in Solid Tumors, version 1.1.
Includes patients with an interval free of platinum-based chemotherapy of at least 180 days but unable to receive further platinum-based chemotherapy (owing to toxic effects or allergic reaction).
For pooled analysis, neoadjuvant therapy, adjuvant therapy, and the combination of both were considered to be 1 line of therapy. Small molecules, hormonal agents, and bevacizumab were not counted in the lines of therapy.
Only patients with known biomarker status were included.